Screener
Ligand Pharmaceuticals LGND AT220 — Financial Royalty Assets, Net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNet.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
| Others | 5,729 | (212) | 5,517 | 5,769 | (214) | 5,555 |
| Total financial royalty assets, net | $209,699 | $(2,489) | $207,210 | $222,375 | $(2,706) | $219,669 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's AT220 — financial royalty assets, net?
- Ligand Pharmaceuticals (LGND) reported AT220 — financial royalty assets, net of $4.33M in Q2 2026.
- What does AT220 — financial royalty assets, net mean?
- This metric represents the current carrying value of royalty assets for the AT220 segment after accounting for all applicable allowances and impairments. It provides the most accurate reflection of the asset's remaining economic value on the balance sheet, which is expected to generate future royalty income. Investors use this figure to assess the net book value of the company's investment in this specific product line and its potential for future earnings contribution.
Ask your AI about Ligand Pharmaceuticals's at220 — financial royalty assets, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude